GlassScriptPhysician profile
Elliott P Vichinsky
NPI 1932147840
$73,367.98
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $31K · 2021: $12K · 2022: $8,100 · 2024: $7,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $29,259.00 | 2020-2022 | |
| Pfizer INC. | $22,380.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $7,114.00 | 2024 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $6,410.70 | 2019 | |
| Chiesi USA, INC. | $3,600.00 | 2020 | |
| Biomarin Pharmaceutical INC. | $2,800.00 | 2022 | |
| Apo-Pharma INC. | $1,804.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Vichinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.